$462.78 Million in Sales Expected for West Pharmaceutical Services Inc. (NYSE:WST) This Quarter

Equities analysts forecast that West Pharmaceutical Services Inc. (NYSE:WST) will post sales of $462.78 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for West Pharmaceutical Services’ earnings, with estimates ranging from $457.05 million to $466.00 million. West Pharmaceutical Services reported sales of $447.50 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.4%. The company is scheduled to announce its next earnings report before the market opens on Thursday, July 25th.

On average, analysts expect that West Pharmaceutical Services will report full-year sales of $1.81 billion for the current financial year, with estimates ranging from $1.80 billion to $1.82 billion. For the next fiscal year, analysts forecast that the business will report sales of $1.95 billion, with estimates ranging from $1.93 billion to $1.97 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.08. West Pharmaceutical Services had a return on equity of 16.38% and a net margin of 12.53%. The business had revenue of $443.50 million for the quarter, compared to the consensus estimate of $431.00 million. During the same quarter in the prior year, the business posted $0.62 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis.

A number of research analysts have recently commented on the company. Zacks Investment Research downgraded Inflarx from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. William Blair restated an “outperform” rating on shares of bluebird bio in a research note on Tuesday, April 23rd. Finally, Jefferies Financial Group raised their price target on EXACT Sciences from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st.

In related news, VP Daniel Malone sold 4,458 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $123.03, for a total transaction of $548,467.74. Following the transaction, the vice president now owns 33,478 shares in the company, valued at approximately $4,118,798.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.70% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. acquired a new stake in West Pharmaceutical Services during the 1st quarter worth approximately $25,000. Berman Capital Advisors LLC acquired a new stake in West Pharmaceutical Services during the 4th quarter worth approximately $27,000. Manchester Capital Management LLC acquired a new stake in West Pharmaceutical Services during the 1st quarter worth approximately $33,000. Quadrant Capital Group LLC lifted its position in West Pharmaceutical Services by 208.7% during the 1st quarter. Quadrant Capital Group LLC now owns 318 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 215 shares during the period. Finally, Icon Wealth Partners LLC acquired a new stake in West Pharmaceutical Services during the 1st quarter worth approximately $46,000. Hedge funds and other institutional investors own 91.90% of the company’s stock.

Shares of WST traded down $0.06 during mid-day trading on Friday, reaching $124.43. The company’s stock had a trading volume of 188,759 shares, compared to its average volume of 252,923. West Pharmaceutical Services has a 12-month low of $91.75 and a 12-month high of $127.06. The firm has a market capitalization of $9.14 billion, a PE ratio of 44.28, a PEG ratio of 3.77 and a beta of 1.30. The company has a current ratio of 2.88, a quick ratio of 2.13 and a debt-to-equity ratio of 0.19. The firm’s 50 day moving average price is $120.60.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 24th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Tuesday, July 23rd. This represents a $0.60 dividend on an annualized basis and a yield of 0.48%. West Pharmaceutical Services’s dividend payout ratio is presently 21.35%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: Yield Curve

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.